-
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
•
NewCo is a new transaction model developed by Chinese innovative drug companies in response to capital winter and internationalization needs. It involves licensing overseas rights of early-stage R&D pipelines to newly established independent companies, bringing in overseas capital and management teams to accelerate development and share risks. This model combines…
-
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
•
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National Medical Products Administration (NMPA) for its investigational drug HBM9378/SKB378, also known as WIN378. This fully human antibody targets thymic stromal lymphopoietin (TSLP) and is intended for the treatment of chronic obstructive pulmonary disease (COPD). Drug…
-
Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
•
Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered into a license agreement with Switzerland-based drug developer Windward Bio AG. Windward Bio, which officially launched with a USD 200 million Series A financing round, has been granted global rights to HBM9378/SKB378, an anti-thymic stromal…
